Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"

被引：0
|
作者：
Groothof, Dion [1 ]
Post, Adrian [1 ]
Bakker, Stephan J. L. [1 ]
机构：
[1] Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands
来源：
CIRCULATION | 2022年 / 146卷 / 02期
关键词：
D O I：
10.1161/CIRCULATIONAHA.122.060263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E5 / E6
页数：2
相关论文
共 50 条
  • [1] Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial
    Lam, Carolyn S. P.
    Ramasundarahettige, Chinthanie
    Branch, Kelley R. H.
    Sattar, Naveed
    Rosenstock, Julio
    Pratley, Richard
    Del Prato, Stefano
    Lopes, Renato D.
    Niemoeller, Elisabeth
    Khurmi, Nardev S.
    Baek, Seungjae
    Gerstein, Hertzel C.
    CIRCULATION, 2022, 145 (08) : 565 - 574
  • [2] Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"
    Lam, Carolyn S. P.
    Gerstein, Hertzel C.
    CIRCULATION, 2022, 146 (02) : E7 - E7
  • [3] Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial (vol 145, pg 565, 2022)
    Lam, Carolyn S. P.
    CIRCULATION, 2023, 147 (23) : E720 - E720
  • [4] Response by Lytvyn et al to Letter Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials"
    Lytvyn, Yuliya
    Bjornstad, Petter
    Udell, Jacob A.
    Lovshin, Julie A.
    Cherney, David Z. I.
    CIRCULATION, 2018, 137 (18) : 1984 - 1985
  • [5] Clinical outcomes of Sodium-glucose cotransporter-2 inhibitors in patients with Type 2 Diabetes Mellitus: An observational study from Pakistan
    Das, Bhagwan
    Sheikh, Aisha
    Ahmed, Bilal
    Islam, Najmul
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2021, 37 (05) : 1342 - 1346
  • [6] Sodium-Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multiethnic Asian Cohort
    Feng, Liang
    Liew, Zhong Hong
    Bee, Yong Mong
    Jafar, Tazeen H.
    KIDNEY MEDICINE, 2025, 7 (03)
  • [7] Response to letter from Du et al. regarding article 'Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?'
    Fawzy, Ameenathul Mazaya
    Rivera-Caravaca, Jose Miguel
    Fauchier, Laurent
    Lip, Gregory Y. H.
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 630 - 633
  • [8] Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Tampaki, Ekaterini Christina
    Tampakis, Athanasios
    Pantos, Costas
    CIRCULATION, 2018, 137 (09) : 982 - 983
  • [9] Letter by Grocott Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials"
    Grocott, Hilary P.
    CIRCULATION, 2018, 137 (18) : 1983 - 1983
  • [10] Impact of baseline FIB-4 score on efpeglenatide benefits on cardiovascular outcomes in people with type 2 diabetes: a participant-level exploratory analysis of the AMPLITUDE-O trial
    Del Prato, Stefano
    Li, Zhuoru
    Ramasundarahettige, Chinthanie
    Branch, Kelley R. H.
    Lam, Carolyn S. P.
    Lopes, Renato D.
    Pratley, Richard
    Rosenstock, Julio
    Sattar, Naveed
    Gerstein, Hertzel C.
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
12345